ARGENX
LIVE

Serial Number

97727259

Owner

ARGENX B.V.

Attorney

Edward T. White

Filing Date

Dec 21, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ARGENX Trademark

Serial Number: 97727259 • Registration: 7491300

ARGENX is a trademark filed by ARGENX B.V. on December 21, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

ARGENX B.V. (22 trademarks)

Industriepark Zwijnaarde 7
B-9052 Zwijnaarde B-9052 , BE

Entity Type: 26

Trademark Details

Filing Date

December 21, 2022

Registration Date

September 3, 2024

Published for Opposition

June 18, 2024

Goods & Services

Pharmaceuticals and medical preparations for therapeutic purposes in the field of immunology and autoimmune diseases; pharmaceutical preparations for the prevention or treatment of autoimmune, antibody-mediated, neuromuscular, hematological, inflammatory, respiratory, kidney, skin, and transplantation-related diseases and disorders, cancer and diseases of the immune system; compositions of antibodies or fragments of antibodies or derivatives of antibodies with therapeutic properties; antibodies or fragments of antibodies or derivatives of antibodies for the prevention or treatment of autoimmune, antibody-mediated, neuromuscular, hematological, inflammatory, respiratory, kidney, skin, transplantation-related diseases and disorders, cancer and diseases of the immune system

Wholesale and retail store services for pharmaceutical preparations in the field of immunology and autoimmune diseases and antibodies or fragments or derivatives of antibodies with therapeutic properties; marketing services and patient information services namely, providing consumer product information in the field of immunology, diseases of the immune system and antibody therapeutics; provision of customer or patient information, namely, providing consumer product information relating to pharmaceutical, medical, healthcare products through an online computer network; administration of patient reimbursement programs

Providing information to patients in the field of auto-immune, antibody-mediated, neuromuscular, hematological, inflammatory, respiratory, kidney, skin, and transplantation-related diseases and disorders, cancer and diseases of the immune system and the treatment thereof; medical consultancy and medical information services relating to biopharmaceutical products

Research and development in the field of immunology, antibody engineering and autoimmune diseases; drug research and development in the field of immunology, antibody technology and autoimmune diseases; scientific and technological services, namely, research, design, analysis, and testing in the field of immunity, autoimmune diseases and antibody engineering; providing medical and scientific research information in the field of pharmaceuticals, clinical trials, research and development

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 3, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Sep 3, 2024 ECDR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Sep 3, 2024 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 3, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 3, 2024 REAP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 3, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 3, 2024 R.PR
POST PUBLICATION AMENDMENT - ENTERED
Jul 12, 2024 CHPB
ASSIGNED TO PETITION STAFF
Jul 10, 2024 APET
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 18, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jun 18, 2024 PUBO
TEAS POST PUBLICATION AMENDMENT RECEIVED
Jun 10, 2024 EPPA
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 29, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 16, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 16, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 16, 2024 CRFA
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
May 15, 2024 GNS2
INQUIRY TO SUSPENSION E-MAILED
May 15, 2024 GNSI
SUSPENSION INQUIRY WRITTEN
May 15, 2024 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Apr 24, 2024 RCCK
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 22, 2024 ERSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Apr 19, 2024 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 19, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 19, 2023 GNSL
SUSPENSION LETTER WRITTEN
Oct 19, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 14, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 14, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 14, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 6, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jun 6, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jun 6, 2023 CNRT
ASSIGNED TO EXAMINER
May 4, 2023 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jan 19, 2023 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 18, 2023 NWOS
NEW APPLICATION ENTERED
Dec 24, 2022 NWAP